Article3 Biotech2022
Exploring actinomycetes natural products to identify potential multi-target inhibitors against
Article in 3 Biotech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Systems-Driven Identification and Experimental Validation of Actinomycetes-Derived Secondary Metabolites as Promising Antileishmanial Agents TargetingACS medicinal chemistry letters · 2026Article
- Protozoan Neglected Tropical Diseases (NTDs) Target Inhibition of Alkaloids fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting with Structural Analogs of Natural Products the Purine Salvage Pathway inTropical medicine and infectious disease · 2024Article
- Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics.Molecular diversity · 2023Article
- Translational vaccinomics and structural filtration algorithm to device multiepitope vaccine for catastrophic monkeypox virus.Computers in biology and medicine · 2023Article
- ACW-02 an Acridine Triazolidine Derivative Presents Antileishmanial Activity Mediated by DNA Interaction and Immunomodulation.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection.Structural chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a neglected tropical disease that mainly affects the poor population of the Indian, African, and South American subcontinent. The increasing resistance to antimonial and miltefosine and frequent toxicity of amphotericin B drives an urgent need to develop an anti-leishmanial drug with excellent efficacy and safety profile. In this study, three sequential docking protocols (HTVS, SP, and XP) were performed to screen the secondary metabolites (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.